Navigation Links
Peramivir Phase 2 Data for the Treatment of Outpatient Influenza to be Presented at the 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy
Date:10/20/2008

hnology partners for further development of its product candidates, that our projected burn rate may not be consistent with our expectations, that BioCryst may not have sufficient cash to continue funding the development, manufacturing, marketing or distribution of its products and that additional funding, if necessary, may not be available at all or on terms acceptable to BioCryst. Please refer to the documents BioCryst files periodically with the Securities and Exchange Commission, specifically BioCryst's most recent Annual Report on Form 10-K, most recent Registration Statement on Form S-3 (File No. 333-145638), Quarterly Reports on Form 10-Q, current reports on Form 8-K which identify important factors that could cause the actual results to differ materially from those contained in the projections or forward-looking statements.

BCRXW


'/>"/>
SOURCE BioCryst Pharmaceuticals
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. BioCryst Reports Preliminary Results From a Phase II Clinical Trial of Peramivir in Subjects With Acute Influenza
2. Isolagen to Host Investor Conference Call to Present an Analysis of the Data from Phase III Wrinkle Studies
3. Peregrine Pharmaceuticals Completes Patient Enrollment In First Stage of Bavituximab Phase II Lung Cancer Trial
4. GeoVaxs DNA and MVA Vaccines Shipped to HIV Vaccine Trials Network for Use in the Upcoming Phase 2a Trial
5. New Data From Head-to-Head Phase 3 Trial Demonstrate That Liraglutide is More Effective Than Exenatide in Treatment of Type 2 Diabetes
6. Nile Therapeutics Announces Positive Interim Data from Phase 2a Study of CD-NP in Patients with Heart Failure
7. Neurobiological Technologies Announces Update Call on Viprinex (TM) Phase 3 Trial Program
8. BioXcel Forms a Corporate Advisory Board for Its Next Phase of Growth
9. BioMS Medicals phase III U.S. multiple sclerosis trial receives positive safety review from Data Safety Monitoring Board
10. TorreyPines Therapeutics Reports Successful End-of-Phase II Meeting With FDA for Tezampanel
11. AEterna Zentaris Completes Patient Recruitment for Second Efficacy Trial of its Phase 3 Program with Cetrorelix in Benign Prostatic Hyperplasia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... Mass. , Jan. 22, 2015   GenoSpace , a ... of tools to enable the broad use of genomic, imaging ... announced the appointment of Michelle Munson , CEO of ... director. Logo - http://photos.prnewswire.com/prnh/20150122/170713 ...
(Date:12/24/2014)... , Dec. 24, 2014 PlasmaTech Biopharmaceuticals, Inc. (NASDAQ: PTBI, ... announced the closing of an underwritten public offering of 3,500,000 ... an aggregate 3,500,000 shares of common stock, at an offering ... warrants have a per share exercise price of $5.00, are ...
(Date:12/24/2014)... Louis, Missouri (PRWEB) December 23, 2014 GMO ... biotechnology company, Syngenta, are in the process of being consolidated ... case is In Re: Syngenta AG MIR 162 Corn Litigation, ... District of Kansas. , Management of the Syngenta GMO corn ...
(Date:12/24/2014)... 2014 According to Ross Selinger, President of ... ITRA Global, the national office market continues to be strong, ... is evidenced by the third quarter’s surprising 3.9% GDP, unemployment ... energy costs have held inflation down and the Fed is ...
Breaking Biology Technology:GenoSpace Expands Board with Appointment of Michelle Munson 2PlasmaTech Biopharmaceuticals, Inc. Announces Closing of Public Offering 2PlasmaTech Biopharmaceuticals, Inc. Announces Closing of Public Offering 3Carey Danis & Lowe Reports on Syngenta GMO Corn Transfer Order 2ITRA Global Reports Long Island Is Out of Sync With The National Office Market 2ITRA Global Reports Long Island Is Out of Sync With The National Office Market 3
... Inverness Medical,Innovations, Inc. (Amex: IMA ) ... dated January 31, 2008 and entitled "Inverness Medical,Innovations ... and Medical Device Conference on February 5, 2008." ... Company,s presentation. The,correct time of the presentation is ...
... Calif., Feb. 1 Edwards Lifesciences,Corporation (NYSE: ... technologies to,treat advanced cardiovascular disease, is scheduled to ... Medical Device,Conference at the Grand Hyatt Hotel in ... M. Abate, Edwards Lifesciences, corporate vice president, chief,financial ...
... Inc.,(Nasdaq: VRUS ) management will be presenting at ... February 11 - 13, 2008 at the,Waldorf-Astoria Hotel in ... provide an overview of the company on Monday,February 11, ... Salon. In,addition, Dr. Michelle Berrey, Pharmasset,s Chief Medical Officer, ...
Cached Biology Technology:Edwards Lifesciences to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference 2Pharmasset to Present at the BIO CEO & Investor Conference 2008 on Monday, February 11th 2
(Date:1/22/2015)... Jan. 21, 2015  Analyst Report Issued by Small Cap IR. ... showed that planet-wide, transactions at merchants on the leading payment ... number of credit, debit, and prepaid cards reached 6.54 billion.  ... of fraudulent card usage in 2012, and credit and debit ...
(Date:1/22/2015)... NEW YORK , Jan. 22, 2015   EyeLock, Inc. ... announced it has appointed Steve Gerber to the ... Gerber will be responsible for leading development of mobile platforms ... 25 years of success and innovation in the semiconductor industry ...
(Date:12/22/2014)... Inc. (NASDAQ: NXTD and NXTDW) ("NXT-ID" or ... mobile commerce market, announces it has retained famous pickpocket, entertainer ... International CES debut of the Wocket™ biometric smart wallet.  ... NXT-ID booth January 6th and 7 th , 2015, demonstrating ...
Breaking Biology News(10 mins):$4.80 Near Term Price Target with "Buy" given by CapRock Research for NXT-ID, Inc. (NASDAQ: NXTD) issued by Small Cap IR 2EyeLock Names Steve Gerber as Senior Vice President of Mobile and Wearables 2NXT-ID Hires Master Pickpocket and Security Consultant Apollo Robbins for Wocket Smart Wallet CES 2015 Debut 2NXT-ID Hires Master Pickpocket and Security Consultant Apollo Robbins for Wocket Smart Wallet CES 2015 Debut 3NXT-ID Hires Master Pickpocket and Security Consultant Apollo Robbins for Wocket Smart Wallet CES 2015 Debut 4
... MD FASEB MARC (Maximizing Access to Research Careers) ... Society for the Study of Reproduction (SSR) Annual Meeting ... These awards are meant to promote the entry of ... of the basic science community and to encourage the ...
... systems work together to paralyze skeletal muscles during rapid eye ... 11 issue of The Journal of Neuroscience . The ... including narcolepsy, tooth grinding, and REM sleep behavior disorder. ... recalled dreams occur your eyes continue to move but ...
... has been awarded a grant expected to total more ... (NIH) National Institute of Allergy and Infectious Diseases (NIAID). ... vaccine against HIV and the disease it causes, AIDS. ... vaccine is urgently needed to slow and eventually eliminate ...
Cached Biology News:Study identifies how muscles are paralyzed during sleep 2Scripps Research Institute wins $77 million to develop AIDS vaccine center 2Scripps Research Institute wins $77 million to develop AIDS vaccine center 3
Gelatin 100 mm Culture Dishes...
BD BioCoat Poly-D-Lysine/Laminin 100 mm Culture Dishes, tissue-culture treated polystyrene with a uniform application of poly-D-lysine and laminin....
BD BioCoat Laminin 100 mm Culture Dishes, tissue-culture treated polystyrene with a uniform application of mouse laminin....
The F40 piston assembly is supplied as two assemblies to service one F40 pump of a BioLogic DuoFlow workstation....
Biology Products: